Please assess the completion status of the following clinical trial:

Trial Title: FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of active C. difficile infection, defined as \> 3 diarrheal stools per day and a positive C. difficile PCR assay~* Hospitalized patient presenting with first relapse of CDI occuring between 15 and 90 days after an index episode of CDI~Exclusion Criteria:~* Pregnancy~* Neutropenia (absolute neutrophil count \<1000/microliters)~* Contraindication for retention enema~* Food allergy not controlled in the donor diet

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMT Group (Intervention Arm) (Type: EXPERIMENTAL): Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
- Antimicrobial Group (Control Arm) (Type: ACTIVE_COMPARATOR): Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.

Based on this trial design, predict the completion outcome and termination type (if applicable).